With the accumulation of ADC experience and the continuous development of technology, more and more carriers other than monoclonal antibodies and payloads other than small molecule drugs are being explored, including PDC, RDC, and antibody-oligonucleotide conjugates (AOC). , double anti-conjugate drugs, antiviral Fc conjugates, nanoparticle conjugates, etc. These broader drug conjugates further expand the market space and provide continued growth momentum for the industry.

However, limited solid tumor penetration and toxicity limitations remain, and resistance mechanisms are beginning to emerge. In order to overcome these limitations, we need to continue to innovate in molecular design and delivery tools to achieve better therapeutic effects to meet clinical needs.

With the strong support of national policies, our innovative drug research and development capabilities have been continuously enhanced in recent years, and overseas cases have also increased. However, in the context of the current tightening of the financing environment, there are still many small and medium-sized XDC-related pharmaceutical companies in the value pipeline. It is necessary to convert cash flow through BD and overseas operations to further support the company's development.

Against this background, we will hold the XDC China2024: Everything Can Be Connected Summit Forum at the Suzhou International Expo Center on August 15-16, 2024, "Based on clinical needs, activating source innovation, focusing on the international market, and exploring the overseas stars of XDC ", we will invite leading domestic XDC entrepreneurs and experts, scholars and other professionals who have made outstanding achievements in the field of conjugate drugs to share and discuss hot topics such as the industry's latest R&D trends, technological innovation, commercialization opportunities, BD and overseas experience, etc. Help China move toward global innovation.